IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland

Pasquale Sansone,1,2 Gianluca Storci,1,3 Simona Tavolini,4 Tiziana Guarnieri,4 Catia Giovannini,1,5 Mario Taffurelli,6 Claudio Ceccarelli,1,7 Donatella Santini,7 Paola Paterini,4 Kenneth B. Marcu,1,8 Pasquale Chieco,1 and Massimiliano Bonafè1,3

1Center for Applied Biomedical Research, St. Orsola-Malpighi University Hospital, 2Department of Pharmacology and Toxicology, 3Department of Experimental Pathology, 4Department of Experimental Evolutionary Biology, 5Department of Internal Medicine and Gastroenterology, 6Department of Surgical and Anesthesiological Sciences, and 7Department of Radiological and Histopathological Sciences, University of Bologna, Bologna, Italy. 8Biochemistry Department, Stony Brook University, Stony Brook, New York, USA.

High serum levels of IL-6 correlate with poor outcome in breast cancer patients. However, no data are available on the relationship between IL-6 and mammary stem/progenitor cells, which may fuel the genesis of breast cancer in vivo. Herein, we address this issue in the MCF-7 breast cancer cell line and in primary human mammospheres (MS), multicellular structures enriched in stem/progenitor cells of the mammary gland. MS from node invasive breast carcinoma tissues expressed IL-6 mRNA at higher levels than did MS from matched non-neoplastic mammary glands. In addition, IL-6 mRNA was detected only in basal-like breast carcinoma tissues, an aggressive breast carcinoma variant showing stem cell features. IL-6 treatment triggered Notch-3–dependent upregulation of the Notch ligand Jagged-1 and promotion of MS and MCF-7–derived spheroid growth. Moreover, IL-6 induced Notch-3–dependent upregulation of the carbonic anhydrase IX gene and promoted a hypoxia-resistant/invasive phenotype in MCF-7 cells and MS. Finally, autocrine IL-6 signaling relied upon Notch-3 activity to sustain the aggressive features of MCF-7–derived hypoxia-selected cells. In conclusion, these data support the hypothesis that IL-6 induces malignant features in Notch-3–expressing stem/progenitor cells from human ductal breast carcinoma and normal mammary gland.

Introduction

IL-6, a major mediator of the inflammatory response, plays a primary role in the pathophysiology of cancer (1, 2). In breast cancer patients, the extent of the increase in serum IL-6 correlates with poor disease outcome and reduced prognosis (3, 4). Although it has been argued that the cytokine may be secreted by cancer cells, the source of the IL-6 in cancer patients has not yet been determined (5, 6). Cancer cells that are exposed to IL-6 or secrete the cytokine as an autocrine factor show malignant features, such as enhanced capacity to invade the extracellular matrix and increased drug resistance (7–10). Accordingly, the inactivation of the gp130 protein, which transduces the signaling of IL-6–type cytokines, has been found to reduce the aggressiveness of breast cancer cells in vivo (11). On the basis of these data, the inhibition of the IL-6/IL-6 receptor interaction with specific antibodies has been proposed as a support cancer therapy (12).

Breast cancer has been proposed as a stem cell disease (13). This hypothesis entails the notion that the growth of the tumor mass relies on the proliferation and self-renewal capacity of a small population of cancer-initiating cells known as cancer stem cells (13–16). Moreover, this notion helps elucidate why the dysregulation of stem cell regulatory pathways plays a causative role in breast cancer (15). In this regard, transgenic mice overexpressing isofoms of Notch, a signaling pathway active in stem cells, are more prone to develop mammary tumors (17). Further, high levels of Notch isoforms have been found to correlate with a poorer prognostic profile and reduced survival in breast cancer patients (18, 19).

Stem/progenitor cells of the mammary gland reside in the basal cell layer (20) and can be expanded in vitro from normal tissues as multicellular spheroids named mammospheres (MS) (21). Prior findings indicate that multicellular MS structures have a clonal origin and have the capacity to reform in vitro after trypsin dissociation. (21). Bilineage (luminal and myoepithelial) progenitors are enriched up to 8 times in MS compared with freshly isolated human mammary cells and constitute virtually 100% of the cells in secondary MS (21, 22). MS regenerate and also form tubuloalveolar structures in matrigel and in immunodeficient mice cleared of fat pads (21–24). Similarly, MS from breast cancer tissues have been shown to proliferate in vitro and also generate tubuloalveolar structures composed of CD44+CD24− cells (25–27). Interestingly, the CD44+CD24− cell population has been shown to be extremely enriched in putative breast cancer stem cells (28).

Both normal and tumor MS (N-MS and T-MS, respectively) have been shown to require active Notch signaling to sustain their survival and proliferation capacity (24–26). Moreover, MS express gp130 and are potential targets of IL-6–type cytokines (21).

Here, we provide evidence that IL-6 gene expression is upregulated in MS obtained from aggressive ductal breast carcinomas and that IL-6 regulates a Notch-3–dependent signaling pathway that promotes self renewal, hypoxia survival, and the invasive potentials of N-MS and T-MS.
to assess the level of IL-6 mRNA, accounting for variability caused by genetic makeup and age (30). We found that, compared with matched N-MS, T-MS from node-invasive tumors (pN3/pN2) expressed increased levels of IL-6 mRNA (Figure 1C). The same comparison performed on T-MS generated from scarcely node-invasive tumors (pN0/pN1) of ductal carcinomas revealed a negligible difference in IL-6 mRNA level between N-MS and T-MS (Figure 1C). Notably, compared with matched N-MS, T-MS obtained from patients affected by pN3/pN2 invasive tumors expressed similar levels of Bmi-1 and CK-5 mRNA and lower levels of breast cancer resistance protein 1 (BCRP-1) and CD133 mRNA, 2 antigens that have been previously associated with (cancer) stem cell phenotype (refs. 31–33; Figure 1C). The higher level of CD133 expression in N-MS compared with T-MS was also evident in IHC analysis (Supplemental Figure 4A).

We then assessed IL-6 mRNA in a set of archival breast tumor samples (Table 2), including ductal (n = 10) and basal-like (n = 6) breast carcinomas, a subtype of cancer showing stem cell features (34–37). This tumor type, similar to MS, was characterized by the expression of CK-5, CK-14, and EGFR protein as well as Bmi-1 and CD133 mRNA (Supplemental Figure 4, B and C), thereby reinforcing the notion of a tight similarity between MS and basal-like breast carcinoma cells (37).

In keeping with this reasoning, we detected IL-6 mRNA in basal-like breast carcinoma tissues, but not in ductal breast carcinoma (Figure 1D). These data indicate that IL-6 expression occurs in MS obtained from aggressive ductal breast carcinoma and in basal-like breast carcinoma tissues, wherein stem cell–like phenotypes are particularly apparent.

**IL-6 promotes MS self renewal and MCF-7–derived spheroid formation.** To assess the functional role of IL-6 expression in MS, we exposed secondary T-MS to a mAb that blocks the IL-6 receptor/ligand interaction (anti–IL-6; 1.5 μg/ml). Exposure of T-MS to anti–IL-6 substantially blunted their secondary regeneration capacity, a functional property that has been referred to as MS self-renewal capability (refs. 21, 22, 25; Figure 2A). Accordingly, we observed that administration of IL-6 (10 ng/ml) to N-MS and T-MS from the same patient yielded an increase in secondary MS formation compared with MS not exposed to the cytokine, a phenomenon that was hampered by the simultaneous addition of anti–IL-6 (1.5 μg/ml; Figure 2B). We further investigated this phenomenon in the context of MCF-7–derived spheroids [MCF-7(S)], which have been recently shown to contain a substantial proportion of CD44+CD24– cells (38). MCF-7(S) expressed high levels of IL-6 mRNA, whereas the mRNA of the cytokine was absent in MCF-7 cells. We then compared IL-6 mRNA expression with cytokine level in MCF-7(S) and MCF-7(S)–derived spheroids. The administration of IL-6 (10 ng/ml) to MCF-7(S)–derived spheroids (Figure 2C) caused a substantial reduction in MCF-7(S) size (Figure 2C). These data indicate that IL-6 mRNA expression promotes growth in suspension and that both autocrine and exogenous IL-6 promotes MS self renewal.

**The MCF-7(S) growth-promoting activity of IL-6 requires Notch-3 gene.** Notch genes play a pivotal role in MS self renewal (24–26). In particular, Notch-3 is highly expressed in N-MS and T-MS (21, 26), and its blockade induces a marked reduction in MS self renewal and survival (26). On these bases, we tested the hypothesis that the effect of IL-6 on MS self renewal and MCF-7(S) formation may depend upon Notch-3 gene expression. We found that administration of anti–IL-6 (1.5 μg/ml) to T-MS for 24 hours yielded downregulation in the level of Notch-3 mRNA and that administration

---

**Table 1**

<table>
<thead>
<tr>
<th>Sample Age (y)</th>
<th>pT</th>
<th>pN</th>
<th>G</th>
<th>NG</th>
<th>ER</th>
<th>HER-2</th>
<th>EGFR</th>
<th>T-MS</th>
<th>N-MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A</td>
<td>55</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>+</td>
<td>0</td>
<td>–</td>
<td>Y</td>
<td>NA</td>
</tr>
<tr>
<td>2A</td>
<td>82</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>+</td>
<td>0</td>
<td>–</td>
<td>Y</td>
</tr>
<tr>
<td>3A</td>
<td>61</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>–</td>
<td>2</td>
<td>–</td>
<td>Y</td>
</tr>
<tr>
<td>4</td>
<td>46</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>+</td>
<td>1</td>
<td>–</td>
<td>Y</td>
</tr>
<tr>
<td>5</td>
<td>73</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>+</td>
<td>0</td>
<td>–</td>
<td>Y</td>
</tr>
<tr>
<td>6</td>
<td>62</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>–</td>
<td>2</td>
<td>–</td>
<td>Y</td>
</tr>
<tr>
<td>7</td>
<td>58</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>1</td>
<td>–</td>
<td>N</td>
</tr>
<tr>
<td>8</td>
<td>83</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>+</td>
<td>3</td>
<td>–</td>
<td>Y</td>
</tr>
<tr>
<td>9</td>
<td>63</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>–</td>
<td>3</td>
<td>–</td>
<td>Y</td>
</tr>
<tr>
<td>10</td>
<td>55</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>3</td>
<td>–</td>
<td>Y</td>
</tr>
<tr>
<td>11</td>
<td>59</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>+</td>
<td>0</td>
<td>–</td>
<td>Y</td>
</tr>
<tr>
<td>12</td>
<td>44</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>+</td>
<td>0</td>
<td>–</td>
<td>Y</td>
</tr>
<tr>
<td>13</td>
<td>59</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>+</td>
<td>1</td>
<td>–</td>
<td>N</td>
</tr>
<tr>
<td>14</td>
<td>39</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>+</td>
<td>1</td>
<td>–</td>
<td>Y</td>
</tr>
<tr>
<td>15</td>
<td>73</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>+</td>
<td>3</td>
<td>–</td>
<td>Y</td>
</tr>
<tr>
<td>16</td>
<td>85</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>–</td>
<td>0</td>
<td>–</td>
<td>N</td>
</tr>
<tr>
<td>17</td>
<td>61</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>+</td>
<td>1</td>
<td>–</td>
<td>Y</td>
</tr>
</tbody>
</table>

pT, tumor size; pN, nodal involvement; G, grading; NG, nuclear grading; HER-2: ErbB-2 receptor; Y, yes; NA, not available; N, no. *mRNA from the tumor tissue was available.

---

**Results**

*High levels of IL-6 mRNA are present in MS from aggressive ductal breast carcinoma and in basal-like breast carcinoma tissues.* T-MS were generated from the tumor tissues of 3 patients with ductal breast carcinoma (samples 1–3; Table 1 and Figure 1A).

T-MS were characterized by immunohistochemistry (IHC). We found that T-MS were composed almost entirely of cells that were CD44+ (97% ± 3%) and CD24− (<1% CD24+; Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI32533DS1), suggesting that the majority of cells in T-MS present a CD44+CD24− cancer stem cell phenotype (28).

Further, cells in T-MS expressed Oct-4 (88% ± 7%), which has been previously reported to hyperexpress T-MS (27), and cytokeratin 5 (CK-5; 22% ± 7%), which identifies the mammary gland basal cell compartment (ref. 20 and Supplemental Figure 1C). The same comparison performed on T-MS generated between N-MS and T-MS (Figure 1C). Notably, compared with matched N-MS, T-MS from node-invasive tumors expressed increased levels of IL-6 mRNA (Figure 1C). The higher level of CD133 expression in N-MS compared with T-MS was also evident in IHC analysis (Supplemental Figure 4A).

RT-PCR analysis revealed that T-MS, but not the tumor tissues from which T-MS were obtained, expressed detectable levels of IL-6 mRNA (Figure 1B). RT-PCR analysis also revealed that, compared with tumor tissues, T-MS expressed high levels of Bmi-1 mRNA, a gene associated with stem cell renewal (23); CD44 mRNA, a gene whose expression has been associated with cancer stem cell phenotype in different organs (28, 29); and CK-5 and Oct-4 mRNA (Figure 1B).

T-MS were then obtained from a set of samples (n = 14) in which the normal mammary gland tissue was also available to generate N-MS (Table 1, samples 4–17).

Similar to T-MS, N-MS lacked CD24 expression and contained cells expressing CD44 (95% ± 3%), CK-5 (14% ± 3%), CK-14 (78% ± 7%), and CK-18 (75% ± 9%; Supplemental Figure 3). The availability of N-MS and T-MS from the same patient allowed us...
of IL-6 (10 ng/ml) to N-MS for 24 hours elicited upregulation of Notch-3 mRNA (Figure 3A). A similar regulation was observed in MCF-7 cells and MCF-7(S) exposed to IL-6 (10 ng/ml for 24 hours) and in MCF-7(S) exposed to anti–IL-6 (1.5 μg/ml for 24 hours; Figure 3B). To better characterize the role of IL-6/Notch-3 interplay in substrate-independent growth, we generated MCF-7(S) using MCF-7 cells stably transduced with a retroviral vector expressing Notch-3–specific (shNotch-3) or control short hairpin RNA (shRNA). We found that MCF-7(S) obtained from control shRNA–transduced MCF-7 cells and generated in the presence of IL-6 (10 ng/ml) showed an increase in size, whereas shNotch-3 MCF-7 cells did not produce MCF-7(S), even in presence of exogenous IL-6 (10 ng/ml; Figure 3C). These data indicate that Notch-3 signaling is of pivotal importance to sustain the IL-6–dependent growth of breast cancer cells in suspension culture.

IL-6 elicits a Notch-3–dependent upregulation of Jagged-1 mRNA expression, which sustains MCF-7(S) formation and promotes MS self renewal. We recently reported that Notch-3 promotes MS survival by interacting with its ligand Jagged-1 (26). Therefore we next evaluated whether Jagged-1 was involved in Notch-3–dependent MS growth. Indeed, either exposing N-MS to IL-6 (10 ng/ml) or adding anti–IL-6 (1.5 μg/ml) to T-MS modulated the expression of Jagged-1 mRNA (Figure 4A). Moreover, we found that in MCF-7 cells, IL-6 elicited upregulation of Jagged-1 mRNA, which was blocked by the coadministration of IL-6 with the MEK/ERK inhibitor UO-126 (Figure 4B). Furthermore, we found that the upregulation of Jagged-1 induced by IL-6 was negligible in shNotch-3 MCF-7 cells and that the transfection of pCDNA3.1 vector encoding Notch-3 intracellular active cleaved fragment (pNICD3) into MCF-7 cells triggered an upregulation of Jagged-1 mRNA, which was prevented by the concurrent administration of UO-126 (Figure 4B). In addition, we observed that MCF-7(S) formation was extremely reduced when MCF-7 cells were transfected with a Jagged-1 specific siRNA compared with scrambled control siRNA (Figure 4C). Finally, we observed that an antibody blocking Jagged-1/Notch-3 interaction reduced MS regeneration capacity (Figure 4D), indicating that the Notch-3/Jagged-1 pathway is functionally relevant for IL-6–induced MS formation. Notably, we also found that basal-like breast carcinoma tissues expressed higher Jagged-1 and Notch-3 mRNA levels than did ductal breast carcinoma tissues (Figure 4E). These data suggest that upregulation of Jagged-1 via Notch-3 signaling is crucial for the growth in suspension of breast cancer cells and MS and that this phenomenon may also occur in basal-like breast cancer tissues.

IL-6 induces a Notch-3–dependent upregulation of carbonic anhydrase IX. ERK upregulation has recently been found to enhance the expression of the hypoxia survival gene carbonic anhydrase IX (CA-IX; refs. 26, 39). Thus given our above observations, we next evaluated whether IL-6 signaling modulates CA-IX gene expression. Indeed, adding IL-6 (10 ng/ml) to N-MS induced upregulation of CA-IX mRNA (Figure 5A). Increased CA-IX expression was also observed in MCF-7 cells exposed to IL-6 (10 ng/ml for 24 hours), whereas
CA-IX gene expression was markedly reduced by the administration of 
UO-126 (Figure 5B). Similar to what we observed for Jagged-1 
(Figure 4B), CA-IX gene expression was inhibited in shNotch-3 
MCF-7 cells, but not control MCF-7 cells, exposed to IL-6, while 
it was enhanced by transfection of the pNICD3 vector but not in 
the presence of UO-126 (Figure 5B). Because CA-IX is a hypoxia 
response gene (39), we investigated whether IL-6 plays a role in 
the hypoxia response. Exposure of MCF-7 cells to hypoxic stimul 
i (100 μM desferoxamine [DFX] or low oxygen tension, <0.1% O 
2) for 48 hours), as well as the exposure of N-MS and T-MS to 50 
μM DFX (48 hours), enhanced the expression of IL-6, Notch-3, and CA-IX 
mRNAs (Figure 5C). Importantly, upon blocking the upregulation of hypoxia-responsive genes with 100 μM DFX, the administration 
of anti–IL-6 (1.5 μg/ml) to MCF-7 cells caused downregulation of 
Notch-3 and CA-IX mRNA. In addition, CA-IX mRNA was also 
downregulated in shNotch-3 MCF-7 cells exposed to 100 μM DFX 
compared with control MCF-7 cells (Figure 5D). Taken together, 
these results indicate the CA-IX gene expression is regulated by the 
IL-6/Notch-3 pathway in MCF-7 cells and MS.

IL-6/Notch-3/CA-IX axis promotes hypoxia survival in MCF-7 and MS.

CA-IX has been found to play a crucial role in hypoxia survival 
of breast cancer cells and MS (26). In keeping with these data, we 
observed a substantial increase compared with matched controls 
in cell death of MCF-7 cells exposed to 100 μM DFX in the pres 
ence of anti–IL-6 (1.5 μg/ml) or transfection with CA-IX–spec 
specific siRNA (Figure 6A). Furthermore, a higher degree of hypoxia-
induced cell death accompanied by downregulation of CA-IX 
mRNA was observed in shNotch-3 MCF-7 cells compared with con 
trol MCF-7 cells (Figure 6A). In line with these results, we found 
that exposure of T-MS to anti–IL-6 or anti-N3 (1.5 and 1 μg/ml, 
respectively) or transfection with CA-IX siRNA, in the presence 
of 50 μM DFX, increased cell death compared with a matched scram 
bled siRNA control (Figure 6B). Interestingly, detectable levels of 
CA-IX mRNA were found only in tissues from basal-like breast 
carcinoma (Figure 6C). These data indicate that IL-6/Notch-3–
induced CA-IX gene expression promotes hypoxia survival in MS 
and support the similarity between the gene expression profiles of MS and 
basal-like breast carcinoma tissues.

IL-6 triggers a Notch-3/CA-IX–dependent increase in the invasiveness of MS 
and MCF-7 cells. The results illustrated in Figure 5B pointed out that IL-6 
induces a Notch-3/ERK–mediated upregulation of CA-IX expression in 
absence of hypoxia. We then investiga 
gated the activity of the IL-6/Notch-3/ 
CA-IX axis in normoxic conditions. We 
found that exposure to IL-6 (10 ng/ml) 
enhanced the capacity of MCF-7 cells 
to invade the extracellular matrix. This 
increase was negligible in shNotch-3 
MCF-7 cells, and it was also substantially 
reduced when CA-IX, but not scrambled, siRNA was administered 
to IL-6–exposed MCF-7 cells (Figure 7A).

Autocrine IL-6 sustains a CA-IX–dependent aggressive phenotype in 
MCF-7–derived, hypoxia-selected cells. Taken together, these results 
suggest that the establishment of an autocrine IL-6 loop may 
engender cancer cells with a substantial growth advantage over 
their normal counterparts. To explore this idea, we next examined 
a MCF-7–derived cell population, HYPO-7, which was obtained 
by selecting parental MCF-7 cells in the presence of 100 μM DFX 
(see Methods). Such cells, cultured for an extensive time period 
(up to 1 year) in the absence of DFX were found to constitutively 
express high levels of IL-6, Notch-3, and CA-IX mRNA (Figure 
8A). We found that, compared with scrambled siRNA, administra 
tion of IL-6 siRNA to HYPO-7 yielded a decrease in Notch-3 and 
CA-IX mRNA expression, an increase in the susceptibility to DFX-
induced cell death, and a reduction in their invasive potential and 
MMP-2 activity (Figure 8A). In agreement with the data obtained 
in MCF-7 cells and MS, we found that the administration of CA-IX, 
but not scrambled, siRNA to HYPO-7 cells recapitulated the pheno 
typic changes induced by IL-6 siRNA in HYPO-7 cells (Figure 
8B). Interestingly, the effects elicited by IL-6 siRNA were also 
observed when HYPO-7 cells were exposed to anti–IL-6 (1.5 μg/ml 
for 24 hours; data not shown). Of particular importance, however, 
was the observation that administration of anti–IL-6 (1.5 μg/ml 
for 24 hours) caused downregulation of IL-6 mRNA in HYPO-7 
cells as well as in MCF-7(S) and T-MS (Figure 8C). These data sug-

Table 2
Clinical-pathologic parameters of 16 archival breast carcinoma tissues assessed by RT-PCR

<table>
<thead>
<tr>
<th>Sample</th>
<th>Age (yr)</th>
<th>pT</th>
<th>pN</th>
<th>G</th>
<th>NG</th>
<th>ER</th>
<th>HER-2</th>
<th>CK-5</th>
<th>CK-14</th>
<th>EGFR</th>
<th>Histotype</th>
<th>Basal-like</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>40</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>IDC</td>
<td>Y</td>
</tr>
<tr>
<td>B</td>
<td>55</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>IDC</td>
<td>Y</td>
</tr>
<tr>
<td>C</td>
<td>71</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>IDC</td>
<td>Y</td>
</tr>
<tr>
<td>D</td>
<td>47</td>
<td>4</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>IDC</td>
<td>Y</td>
</tr>
<tr>
<td>E</td>
<td>78</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>IDC</td>
<td>Y</td>
</tr>
<tr>
<td>F</td>
<td>65</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>IDC</td>
<td>Y</td>
</tr>
<tr>
<td>G</td>
<td>57</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>IDC</td>
<td>N</td>
</tr>
<tr>
<td>H</td>
<td>57</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>IDC</td>
<td>N</td>
</tr>
<tr>
<td>I</td>
<td>42</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>IDC</td>
<td>N</td>
</tr>
<tr>
<td>J</td>
<td>49</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>IDC</td>
<td>N</td>
</tr>
<tr>
<td>K</td>
<td>78</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>IDC</td>
<td>N</td>
</tr>
<tr>
<td>L</td>
<td>64</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>IDC</td>
<td>N</td>
</tr>
<tr>
<td>M</td>
<td>63</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>IDC</td>
<td>N</td>
</tr>
<tr>
<td>N</td>
<td>63</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>IDC</td>
<td>N</td>
</tr>
<tr>
<td>O</td>
<td>60</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>IDC</td>
<td>N</td>
</tr>
<tr>
<td>P</td>
<td>60</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>IDC</td>
<td>N</td>
</tr>
<tr>
<td>Q</td>
<td>55</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>IDC</td>
<td>N</td>
</tr>
<tr>
<td>R</td>
<td>42</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>IDC</td>
<td>N</td>
</tr>
</tbody>
</table>

pT, tumor size; pN, nodal involvement; G, grade; NG, nuclear grade; HER-2: ErbB-2 receptor; IDC, infiltrating-ductal-breast carcinoma; Y, yes; N, no. Basal-like breast carcinomas were diagnosed as CK-5- and/or CK-14–, EGFR–, ER–, and HER-2–negative or –low (0 or 1) ductal breast carcinomas (34, 35).
gest that autocrine IL-6 production could promote the aggressiveness of breast cancer cells.

IL-6 induces an autocrine IL-6 loop that triggers Notch-3–dependent aggressive behavior in MCF-7 cells. Prompted by these observations, we reasoned that IL-6 might regulate the production of its own mRNA. Accordingly, we found that administration of IL-6 (10 ng/ml) upregulated IL-6 mRNA in MCF-7 cells and N-MS (Figure 9A). Furthermore, once exposed to IL-6 (10 ng/ml for 24 hours), MCF-7 cells expressed IL-6 mRNA, even 2 weeks after the withdrawal of IL-6 from the medium (Figure 9B), suggesting that IL-6 autoregulation might perpetuate phenotypic changes caused by exposing breast cancer cells to IL-6. Compared with untreated MCF-7 cells, the cells described above displayed upregulation of Notch-3 and CA-IX mRNA levels, paralleled by an enhancement in their invasive potential and an increase in MMP-2 activity (Figure 9B). The gene upregulation and the increase in invasive behavior of MCF-7 cells 2 weeks after withdrawal of IL-6 was abolished by administration of anti–IL-6 (1.5 μg/ml), respectively (n = 3). *P = 0.027, **P = 0.020, *P = 0.048, **P = 0.035, ANOVA plus post-hoc tests adjusted for multiple comparisons. (C) RT-PCR analysis of IL-6 mRNA in MCF-7 and day 2 MCF-7–derived spheroids and MCF-7(S) generated in the presence or absence of anti–IL-6 (1.5 μg/ml). Also shown are phase-contrast microscopy analysis and MCF-7(S) size distribution. n denotes the number of spheroids counted for each sample. *P = 0.02, Monte Carlo χ² test. β₂₃ was assessed as quantitative control for RT-PCR analysis. Scale bars: 100 μm.

Figure 2
IL-6 sustains MS self renewal and MCF-7 spheroid formation. (A) Day 7 secondary T-MS, generated from primary T-MS in the presence or absence of the mAb anti–IL-6, which blocks the IL-6 receptor/ligand interaction (1.5 μg/ml). Phase-contrast microscopy analysis and number of MS per well (n = 3). *P = 0.029, **P = 0.042, ANOVA. (B) Phase-contrast microscopy analysis and number of MS per well in day 7 secondary T-MS and N-MS generated from primary MS in the presence or absence of IL-6 (10 ng/ml) and anti–IL-6 (1.5 μg/ml), respectively (n = 3). §P = 0.027, §§P = 0.020, *P = 0.048, **P = 0.035, ANOVA plus post-hoc tests adjusted for multiple comparisons. (C) RT-PCR analysis of IL-6 mRNA in MCF-7 and day 2 MCF-7–derived spheroids and MCF-7(S) generated in the presence or absence of anti–IL-6 (1.5 μg/ml). Also shown are phase-contrast microscopy analysis and MCF-7(S) size distribution. n denotes the number of spheroids counted for each sample. *P = 0.02, Monte Carlo χ² test. β₂₃ was assessed as quantitative control for RT-PCR analysis. Scale bars: 100 μm.
ment that an IL-6 autocrine loop could induce long-term enhancement in the aggressive features of breast cancer cells by sustaining upregulation of the Notch-3/CA-IX axis.

Discussion
The present work was prompted by the remarkably consistent finding that high IL-6 serum levels in breast cancer patients are associated with poor outcome and by the accumulating evidence suggesting that IL-6 exerts a direct role in the upregulation of malignant features in breast cancer cells (1–8). Herein we investigated the physiological effects and regulation of IL-6 in MS, which can be considered a suitable in vitro model for normal and tumor stem/progenitor cells of the mammary gland (21–27).

In regard to the stem cell phenotype of MS, we show here that MS express a variety of genes that are upregulated in normal and cancer stem cell from various tissues, such as Bmi-1 (23, 40), CD44 (28, 29), Oct-4 (27), BCRP-1 (33), and CD133 (31, 32). In particular, N-MS and T-MS are almost entirely composed of CD44+/CD24− cells (the so-called breast cancer stem cell phenotype; refs. 27, 28, 41) and a subpopulation of cells (differing 10%–20% in N-MS and T-MS) expressing CD133 protein. Moreover, N-MS and T-MS express the CK-5 gene, which characterizes the basal cell compartment in which stem/progenitor cells of the mammary gland are harbored in vivo (20). In this regard, recent data suggest that CK-5/CD44+, Bmi-1–expressing cells represent cancer stem cells of head and neck squamous carcinoma (40). Overall, the available data support the notion that MS were substantially enriched in stem/progenitor cells compared with the tissues from which they were obtained.

We provide evidence that T-MS obtained from node-invasive tumors expressed higher IL-6 mRNA levels than MS obtained from normal tissue of the same patients. Conversely, no difference was found when MS from scarcely invasive tumors were examined. We also found that IL-6 mRNA levels were readily detected ex vivo only in CK-5+ basal-like breast carcinoma tissues, an uncommon form of biological aggressive breast carcinoma with stem cell–like features, including high levels of CD133 and CD44 expression (34–37). We also showed that these tumors expressed high levels of the stem cell regulatory gene Bmi-1, which was recently shown to be expressed at high levels in T-MS compared with their differentiated epithelial progeny (23). In addition, Bmi-1 is also upregulated in CD44+/CD24− breast cancer cells (23) and is highly expressed in a CK-5+/CD44+ subpopulation of putative head and neck squamous carcinoma cancer stem cells (40). We also document that like basal-like carcinoma cells, T-MS also expressed CK-5/14, EGFR, CD133, Bmi-1, and IL-6. Thus T-MS derived from ductal breast carcinoma would appear to possess at least some of the stem cell–like characteristics of basal-like breast carcinoma.

Our findings on basal-like breast carcinomas support the hypothesis that IL-6 gene expression is related to breast cancer stem cell phenotype. Accordingly, it has been shown that IL-6 gene expression is high in breast cancer cell lines enriched in CD44+/CD24− invasive cells (16). Moreover, IL-6 gene expression showed up in MCF-7–derived spheroids (our present results), which have been shown to contain a high proportion of CD44−/CD133+ putative breast cancer stem cells (38). Overall, these data support the existence of a tight relationship between cancer stem cells and IL-6 expression.

Figure 3
IL-6 induces Notch-3 gene upregulation and Notch-3–dependent MCF-7(S) formation. (A) RT-PCR analysis of Notch-3 mRNA in day 10 primary N-MS in the presence or absence of IL-6 (10 ng/ml) and in T-MS in the presence or absence of anti–IL-6 (1.5 μg/ml) for 24 hours. (B) RT-PCR analysis of Notch-3 mRNA in MCF-7 cells cultured in the presence or absence of IL-6 (10 ng/ml) and in MCF-7(S) in the presence or absence of anti–IL-6 (1.5 μg/ml) or IL-6 (10 ng/ml) for 24 hours. (C) Day 7 MCF-7(S) generated from MCF-7 cells infected with a pSuper-Puro retroviral vector encoding a Notch-3–specific (N3) or control (CT) shRNA (sh) in the presence or absence of IL-6 (10 ng/ml). Phase-contrast microscopy analysis, MCF-7(S) size distribution (n denotes number of spheroids counted per sample), and Western blot analysis of Notch-3 and β-actin protein levels. *P = 0.034, Monte Carlo χ² test. β-actin was assessed as quantitative control for RT-PCR analysis. Scale bars: 100 μm.
Moreover, we also provide evidence that the effects of IL-6 on MS required a functional Notch-3 signaling pathway. Notch-3, a member of the stem cell regulatory Notch family that governs stem cell homeostasis and turnover across species, modulates morphogenetic processes in the mammary gland; when hyperexpressed in transgenic mice, Notch-3 also promotes mammary gland carcinogenesis (17). Interestingly, the Notch-3–dependent activation of the ERK pathway has been reported in both lung cancer and lymphoma cell models (26, 42, 43). Here, we show that Notch-3–dependent ERK activation in breast cancer via IL-6 targeted the

Figure 4
Notch-3/Jagged-1 interplay sustains MCF-7(S) formation and MS self-renewal. (A) Day 10 primary N-MS and T-MS cultured in the presence or absence of IL-6 (10 ng/ml) or anti–IL-6 (1.5 μg/ml) for 24 hours. RT-PCR analysis of Jagged-1 mRNA. (B) RT-PCR analysis of Jagged-1 mRNA and Western blot analysis of phosphorylated ERK and total ERK protein in MCF-7 cells exposed to IL-6 (10 ng/ml) in the presence or absence of the MEK1 inhibitor UO-126 (20 μM) or DMSO for 24 hours, in shNotch-3 and control MCF-7 cells exposed to IL-6 (10 ng/ml for 24 hours), in MCF-7 cells transfected with 1 μg pNICD3 or empty control vector (pEMPTY) for 24 hours, and in MCF-7 cells transfected with pNICD3 in the presence or absence of UO-126 (20 μM) or DMSO. (C) Day 7 MCF-7(S) generated from MCF-7 cells transfected with Jagged-1–specific or scrambled (JAG1 and SCR, respectively) siRNA (1 μg, 72 hours’ pre-exposure). RT-PCR analysis of Jagged-1 mRNA, phase-contrast microscopy analysis, and MCF-7(S) size distribution. *P = 0.001, Monte Carlo χ² test. (D) Day 7 secondary N-MS generated in the presence of IL-6 (10 ng/ml) and in the presence or absence of anti-N3 mAb, which blocks Notch-3 activity (1.5 μg/ml). Shown are phase-contrast microscopy and N-MS size distribution (n denotes number of spheroids counted per sample). §P = 0.039, **P = 0.009, Monte Carlo χ² plus post-hoc tests adjusted for multiple comparisons. (E) RT-PCR analysis of Jagged-1 and Notch-3 mRNA (ratio to β2μ) in basal-like or ductal carcinoma tissues. #P = 0.005, §§P = 0.042, Mann-Whitney test. β2μ was assessed as quantitative control for RT-PCR; β-actin was assessed as quantitative control for Western blot. Scale bars: 100 μm.
simultaneously lowers the pH in the extracellular space, thereby decreasing the concentration of basic equivalents in the cytoplasm, which favors cancer cells and MS. CA-IX catalyzes carbonic dioxide hydrolysis and is upregulated by IL-6 and sustained the invasive potential of breast cells and also to ductal breast carcinoma stem cells.

The IL-6/Notch-3 axis may confer a growth advantage to basal-like carcinoma subtypes (34), we hypothesize that the IL-6/Notch-3/Jagged-1 gene expression correlated with a basal-like breast carcinoma phenotype. Because the IL-6 receptor is expressed at higher levels in basal-like breast carcinomas than in other breast carcinoma subtypes (49), we show that IL-6 upregulated its own mRNA, thus perpetuating the effects of transient IL-6 exposure of breast cancer cells. In addition, this autocrine IL-6 loop required active Notch-3 expression. Hence, our data suggest that the upregulation of IL-6 gene expression in response to stress conditions (hypoxia) or to inflammation (IL-6 itself) may be maintained by an autocrine mechanism in Notch-3 stem/progenitor cells of the mammary gland.

Of note, in this investigation we show that IL-6 triggers self renewal and the invasive capacity of MS obtained from normal mammary tissue. At first glance, this finding could be surprising. However, we must consider that the inflammatory response is a physiologic mechanism aimed at repairing damaged tissues (51). It is therefore conceivable that stem/progenitor cells are able to respond to an inflammatory stimulus (such as IL-6) by a process that promotes proliferation (and self renewal) and stimulates the migration toward locations where tissue repair is required. In this regard, we examined the capacity of MS to generate 3-dimensional structures, that is, to migrate into matrigel and to generate multi-acinar and acinar/ductal structures (ref. 52 and Supplemental Methods). As shown in Supplemental Figure 5, we obtained preliminary evidence that such a morphogenic capacity of MS (upper panel), as well as that of cells derived from the trypsin disgregation of normal MS (lower panel), may be enhanced by IL-6 administration. Indeed, only in IL-6-administered cultures did we observe features recalling acinar structure with a hollow lumen and ductal branching (arrow and arrowhead, respectively, lower panel). These data, together with those reported previously (24), support the hypothesis that Notch signaling plays a role in mammary gland morphogenesis and therefore suggest that IL-6 may enhance the morphogenic capacity of mammary gland stem/progenitor cells. Instead, we observed that CD44/CK-5–expressing progenitor cells. Instead, we observed that CD44/CK-5–expressing progenitor cells. Instead, we observed that CD44/CK-5–expressing progenitor cells.

CA-IX, a hypoxia survival gene. Importantly, siRNA knockdown experiments revealed that both Notch-3 and Jagged-1 were functionally required for spheroid formation and for MS self renewal. Consequently, our data suggest that IL-6 may trigger a potential autocrine/paracrine Notch-3/Jagged-1 loop to boost stem/progenitor self renewal in the mammary gland. Furthermore, in agreement with previous findings (18, 19, 37), we show that Jagged-1 gene expression correlated with a basal-like breast carcinoma phenotype. Because the IL-6 receptor is expressed at higher levels in basal-like breast carcinomas than in other breast cancer subtypes (34), we hypothesize that the IL-6/Notch-3/Jagged-1 axis may confer a growth advantage to basal-like carcinoma cells and also to ductal breast carcinoma stem cells.

We also showed that the CA-IX hypoxia survival gene was upregulated by IL-6 and sustained the invasive potential of breast cancer cells and MS. CA-IX catalyzes carbonic dioxide hydrolisis (44) to facilitate survival under conditions of hypoxia by increasing the concentration of basic equivalents in the cytoplasm, which simultaneously lowers the pH in the extracellular space, thereby creating a favorable environment for the activation of the extracellular matrix degrading enzymes such as MMP-2 (45, 46). Remarkably, higher MMP-2 expression has been associated with poor prognosis in breast cancer (46). In addition, CA-IX hyperexpression has been associated with reduced survival and poor outcome in breast cancer patients (47, 48), and it has also been found to be overexpressed in basal-like breast carcinomas (49, 50). Overall, the upregulation of CA-IX and Jagged-1 adds to a growing number of genes (i.e., CK-5, CK-14, EGFR, CD133, CD44, Bmi-1, and IL-6) that also convey a tight similarity between T-MS and basal-like breast carcinoma. Finally, we present data regarding the autocrine IL-6 loop in breast cancer cells. In particular, we showed that IL-6 upregulated its own mRNA, thus perpetuating the effects of transient IL-6 exposure of breast cancer cells. In addition, this autocrine IL-6 loop required active Notch-3 expression. Hence, our data suggest that the upregulation of IL-6 gene expression in response to stress conditions (hypoxia) or to inflammation (IL-6 itself) may be maintained by an autocrine mechanism in Notch-3 stem/progenitor cells of the mammary gland.

Figure 5

IL-6/Notch-3 cross-talk promotes the upregulation of CA-IX mRNA and protein. (A) RT-PCR analysis of CA-IX mRNA in day 10 primary N-MS cultured in the presence or absence of IL-6 (10 ng/ml) for 24 hours. (B) RT-PCR analysis of CA-IX mRNA and Western blot analysis of CA-IX (phosphorylated ERK, total ERK, and β-actin protein levels shown in Figure 4B) in MCF-7 cells exposed to IL-6 (10 ng/ml for 24 hours) in the presence or absence of UO-126 (20 μM) or DMSO. (C) RT-PCR analysis of IL-6, Notch-3, and CA-IX mRNA in MCF-7 cells exposed to low oxygen (<0.1% O2) or 100 μM DFX and in N-MS and T-MS exposed to 50 μM DFX for 48 hours. (D) RT-PCR analysis of Notch-3 and CA-IX mRNA in MCF-7 cells in the presence or absence of anti–IL-6 (1.5 μg/ml) and in shNotch-3 and control MCF-7 cells exposed to IL-6 (10 ng/ml for 24 hours), Western blot analysis of Notch-3 and β-actin protein. β-actin was assessed as quantitative control for RT-PCR analysis.
Figure 6
The IL-6/Notch-3/CA-IX axis promotes hypoxia survival. (A) MCF-7 cells in the presence or absence of DFX (100 μM for 48 hours) and in the presence or absence of anti–IL-6 (1.5 μg/ml for 24 hours), with transient transfection with the CA-IX–specific or scrambled siRNA (1 μg for 72 hours), and shNotch-3 and control MCF-7 cells. Shown are Western blot analysis of Notch-3 and β-actin protein and cell death analysis and RT-PCR analysis of Notch-3 and CA-IX mRNA (n = 3). *P = 0.017, **P = 0.008, ***P = 0.002, ANOVA. (B) Cell death analysis and RT-PCR analysis of Notch-3 and CA-IX mRNA in day 7 secondary T-MS exposed to 50 μM DFX for 48 hours in the presence or absence of anti–IL-6 (1.5 μg/ml for 48 hours) or anti-N3 (1.5 μg/ml for 48 hours) or transfected with CA-IX or scrambled siRNA (1 μg for 72 hours). n = 3 per group. #P = 0.022, ##P = 0.025, ###P = 0.044, ANOVA. (C) RT-PCR analysis and representative IHC analysis of CA-IX protein expression of breast carcinoma tissues from patients affected by basal-like or ductal breast carcinoma (see Table 2). Data are shown as CA-IX/β2μ mRNA ratio. §P = 0.002, Mann-Whitney test. β2μ was assessed as quantitative control for RT-PCR analysis. Scale bar: 100 μm.
matrigel produce cells that lose the expression of some stem cell markers (such as Oct-4 and CK-5) and acquire the expression of CD24, but cannot generate 3-dimensional structures in matrigel (upper right panel), whereas both luminal (CK-18) and myoepithelial (CK-14) markers are expressed (lower right panel). This finding supports the notion that N-MS and T-MS from the same individual have different functional properties and that the latter are endowed with an aberrant/defective capacity to differentiate (24).

Figure 7
IL-6/Notch-3 cross-talk enhances the invasive potential of MS and MCF-7 cells by means of CA-IX mRNA upregulation. (A) Boyden invasion chamber assay in MCF-7 cells, in shNotch-3 and control MCF-7 cells, and in MCF-7 cells transiently transfected with scrambled or CA-IX siRNA (1 μg, 72 hours’ pre-exposure), in the presence or absence of IL-6 (10 ng/ml for 24 hours). n = 5 per group. *P = 0.0001, **P = 0.0001, ***P = 0.0001, ANOVA. Inset: RT-PCR analysis of CA-IX mRNA in cells administered scrambled or CA-IX siRNA. (B) Boyden chamber invasion assay of day 7 secondary T-MS in the presence or absence of anti-IL6 (1.5 μg/ml for 24 h) or transfected with IL-6 or CA-IX or scrambled siRNA (1 μg, 72 hours’ pre-exposure). n = 3 per group. *P = 0.003, **P = 0.042, ***P = 0.0001, ANOVA. RT-PCR analysis of IL-6 and CA-IX mRNA is shown. (C) Boyden chamber invasion assay of day 7 secondary N-MS exposed to IL-6 (10 ng/ml for 24 hours) in the presence or absence of anti-N3 (1.5 μg/ml for 24 hours) or scrambled or CA-IX siRNA (1 μg, 72 hours’ pre-exposure). n = 3 per group. *P = 0.036, **P = 0.037, ***P = 0.0001, ANOVA. RT-PCR analysis of IL-6, CA-IX, and β2μ mRNA is shown. (D) Zymographic analysis of MMP-2 activity in shNotch-3 and control MCF-7 cells in the presence or absence of IL-6 (10 ng/ml for 24 hours) and in MCF-7 cells exposed to IL-6 (10 ng/ml for 24 hours) transfected with CA-IX or scrambled siRNA (1 μg, 72 hours’ pre-exposure). n = 3 per group. *P = 0.032, **P = 0.025, ***P = 0.027, ANOVA.
It may be indeed argued that the N-MS studied in this investigation were obtained from breast cancer patients. However, although a field effect can not be completely excluded, it has been recently demonstrated that in the human breast, no detectable changes in gene expression are found when non-neoplastic tissues from cancer patients are compared with normal samples from women without cancer (53). Nevertheless, although it is reasonable that IL-6 could participate in the homeostatic mechanism of a normal mammary gland, it has long been established that chronic inflammation, and the sustained upregulation of its mediators, is a cancer-predisposing condition (51). In this regard, recent data indicate that inflammatory cells such as macrophages and lymphocytes promote cancer growth in the mammary gland (54, 55). Although the role of inflammation in breast cancer has long been criticized, recent experimental and epidemiological data indicate that breast cancer growth may be promoted by local and distant inflammatory processes (such as those in the gut), in agreement with the hypothesis that soluble factors link inflammation to breast cancer (56). In regard to this issue, it is worth mentioning that IL-6 serum levels increase with age (30) and that aging is a major risk factor for breast cancer (57). Hence, we speculate that altered IL-6 gene expression in dysregulated mammary gland/stem progenitor cells

---

**Figure 8**

Autocrine IL-6 loop sustains a CA-IX–dependent malignant phenotype in HYPO-7 cells. (A) HYPO-7, a MCF-7–derived cell population, in the presence of IL-6 or scrambled siRNA (1 μg, 48 hours' pre-exposure). RT-PCR analysis of IL-6, Notch-3, and CA-IX mRNA; cell death analysis in the presence of DFX (600 μM for 48 hours); and Boyden chamber invasion assay (n = 5) and zymographic analysis (n = 3) of MMP-2 activity (24 hours). *P = 0.042, **P = 0.0001, ***P = 0.015, ANOVA. (B) HYPO-7 cells in the presence of CA-IX or scrambled siRNA (1 μg, 48 hours' pre-exposure). RT-PCR analysis of IL-6, Notch-3, and CA-IX mRNA; cell death analysis in the presence of DFX (600 μM for 48 hours); and Boyden chamber invasion assay (n = 5) and zymographic analysis (n = 3) of MMP-2 activity (24 hours). #P = 0.034, ##P = 0.0001, ###P = 0.018, ANOVA. (C) HYPO-7 cells, MCF-7(S), and T-MS exposed to anti–IL-6 (1.5 μg/ml) for 24 hours. RT-PCR analysis of IL-6 mRNA level. β2μ was assessed as quantitative control for RT-PCR analysis.
may be a contributory factor linking aging to breast cancer risk. In conclusion, the findings indicate that IL-6 is a potent promoter of malignant features in Notch-3 expressing normal and tumor stem/progenitor cells of the mammary gland.

Methods

Chemicals and reagents. Anti–Notch-3, a mAb that blocks the activation of Notch-3 protein by inhibiting the Notch-3/Jagged-1 interaction, was purchased from R&D. Anti–IL-6, a mAb that blocks the IL-6 receptor/ligand interaction, and recombinant human IL-6 were purchased from Sigma-Aldrich. DFX (Sigma-Aldrich) was used as hypoxia mimetic (26); UO-126 (Sigma-Aldrich) was used as MEK1 inhibitor.

Generation of MS from normal and ductal breast carcinoma tissue specimens. Seventeen fresh surgical specimens, obtained from patients with ductal breast carcinoma who underwent quadrantectomy or mastectomy, were collected to generate MS (Table 1). Normal and tumor samples were histologically characterized (as reported below) to ensure the proper classification of normal and tumor tissue. Particular care was paid to generate MS from specimens in which only normal or tumor tissues were detectable at histological examination. The set of samples consisted of a subset of tumor specimens (n = 3) in which the mRNA of the tumor tissues from which the MS originated was available as well as a subset of specimens (n = 14) in which even the normal tissue from the same patient was available (Table 1). MS were obtained as previously described (21–27), except that the methodology was downscaled to deal with low amounts of tissues (300–900 mg; ref. 26). Briefly, tissues were placed in sterile Epicult (StemCell Technologies), minced with sterile scalpels, and incubated for 6–12 hours in the presence of 1,000 U Collagenase/Hyaluronidase enzyme mix (StemCell Technologies). Samples were centrifuged at 80 g for 2 minutes, and the pellet was digested by Dispase and DNAse for 3 minutes (StemCell Technologies) and then pelleted.

Figure 9

Autocrine IL-6 loop sustains a Notch-3/CA-IX–dependent aggressive phenotype in MCF-7 cells. (A) RT-PCR analysis of IL-6 mRNA in MCF-7 cells and N-MS exposed to IL-6 (10 ng/ml) for 24 hours. (B) MCF-7 cells exposed to IL-6 (10 ng/ml for 24 hours) and assessed at various times (1 or 2 weeks) after the withdrawal of the cytokine. RT-PCR analysis of IL-6, Notch-3, and CA-IX mRNA and Boyden chamber invasion assay (n = 5) and zymographic analysis (n = 3) of MMP-2 activity (24 hours). *P = 0.010, **P = 0.012, ***P = 0.002, ANOVA with post-hoc test for multiple comparisons. (C) MCF-7 cells exposed to IL-6 (10 ng/ml) and assessed for 24 hours and 2 weeks after cytokine withdrawal in the presence or absence of anti–IL-6 (1.5 μg/ml) for 24 hours. RT-PCR analysis of IL-6, Notch-3, and CA-IX mRNA and Boyden chamber invasion assay (24 hours). n = 5 per group. **P = 0.004, ANOVA with post-hoc test for multiple comparisons. (D) RT-PCR analysis of IL-6 and CA-IX mRNA, Western blot analysis of Notch-3 and β-actin protein level, and Boyden chamber invasion assay (24 hours) in shNotch-3 and control MCF-7 cells either untreated or exposed to IL-6 for 24 hours and assessed 2 weeks after cytokine withdrawal (n = 5). §P = 0.001, ANOVA with post-hoc test for multiple comparisons. (E) Boyden chamber invasion assay (24 hours) and RT-PCR analysis of CA-IX mRNA in cells as in C and D transfected with CA-IX or scrambled siRNA (1 μg, 48 hours’ pre-exposure). n = 5 per group. §§P = 0.002, ANOVA. β2μ was assessed as quantitative control for RT-PCR analysis.
Cell death was induced by exposing MCF-7 cells, HYPO-7 cells, and MS to DFX at concentrations of 100, 600, and 1,000 μg/ml, respectively, following previously described protocols (26). Cell attachment plates (Corning) were filled with 3 ml mammary epithelial growth medium (MEGM, Cambrex) containing 10% FBS (Euroclone). Hypoxia (<0.1% O2) was induced in collagen (Sigma-Aldrich) 2 hours before fixation in formalin. Tissues were histologically classified according to WHO criteria (58) and graded following the classification described by Elston and Ellis (59). The tumors were also typed by nuclear grading and classified as mild, moderate, and severe nuclear atypia (graded 1, 2, and 3, respectively). Tumor size and auxiliary lymph node involvement were also recorded using pTNM (UICC) pathological staging criteria (59). Serial sections of formalin-fixed, paraffin-embedded samples were dewaxed, rehydrated, and subjected to antigen retrieval treatment. Tumor sections were stained using mAbs against estrogen receptor (ER; clone 1D5), CK-5 (clone DS/16B4), and EGFR (clone c-20; Santa Cruz); CD44 and CD24 (clone 156-3C11 and clone 2A2; Miltenyi Biotec) and E-cadherin (clone nCH38; DakoCytomation). Antigens were unmasked with Tris-EDTA, pH 9.0, at 98°C for 20 minutes, except for CA-IX antibody. Endogenous peroxidase activity was inhibited using a 0.5% H2O2 solution in methanol for 20 minutes, and sections were processed for IHC with a non–biotin-amplified avidine-biotin complex (DakoCytomation). Anticam1 and −4, −8, and −10 antibodies were used at dilutions of 1:50, 1:150, and 1:100, respectively. Sections of N-MS and T-MS were stained with CA-IX (M-75; kindly provided by J. Pastorek, Slovak Academy of Sciences, Bratislava, Slovak Republic). Sections of N-MS and T-MS were stained with ABC-2 (1D5), −4, −8, and −10 antibodies were used at dilutions of 1:50, 1:150, and 1:100, respectively. Sections of N-MS and T-MS were stained with ABC-2 (1D5), −4, −8, and −10 antibodies were used at dilutions of 1:50, 1:150, and 1:100, respectively.
Beta-actin, annealing temperature 58°C, amplicon length 180 bp, forward 5’-ACCCCAAATAGAAAAGATGA-3’; reverse 5’-ATCCTCAAAACCTCCAGA-3’. PCR primers and reagents were purchased from Invitrogen.

Boydren chamber invasion assay. Cell invasion into Matrigel was assessed by using Boydren chambers (New Technologies Group), containing a polyvinyl-pyrrolidone free polycarbonate filters with 8-μm pores, coated with 15 μg Matrigel (Sigma-Aldrich). Cells (1 x 10⁶) and trypsins disaggregated MS (1-5 x 10² cells) were seeded in the upper chamber in serum-free medium in the presence or absence of IL-6 (10 ng/ml) or anti-IL-6 (1.5 μg/ml); complete medium was placed in the lower compartment as chemoattractant. In several experiments cells and MS were also transfected with appropriate siRNA for 48 hours and then collected, resuspended in 500 μl in the presence of IL-6 (10 ng/ml) or anti-IL-6 (1.5 μg/ml), and seeded in the upper chamber for 24 hours at 37°C in a 5% CO₂ atmosphere.

At the end of incubation, noninvading cells were removed from the upper surface of the filters, and invading cells in the lower surface were fixed in ice-cold methanol, stained with Toluidine Blue staining (Sigma-Aldrich), and scored as the mean number of invaded cells per 5 random optical fields, in 3 independent experiments, at x20 magnification.

Gelatin zymography. MMP-2 activity was determined by gelatin zymography. Briefly, proteins of collected media were precipitated with 1:4 (vol/vol) ice-cold methanol overnight at –20°C, solubilized with sample buffer without mercaptoethanol (1 M Tris-HCl, pH 6.8, 2% SDS, 10% glycerol) and loaded into 10% SDS-polyacrylamide gel containing 1 mg/ml gelatine (Sigma-Aldrich). Gel was then incubated in a developing buffer (100 mM Tris- HCl, 10 mM CaCl₂, 20 mM NaCl, pH 7.6) overnight at 37°C, stained for 2 hours with 1% Coomassie Brilliant Blue R-250, and finally desalted in a solution containing 10% acetic acid and 40% methanol. MMP-2 proteolytic activity was quantified using a semiautomated image analysis (GelDoc; BioRad Laboratories).

**Western blot.** Cell lysates were prepared, run, and blotted using standard methodologies, and probed specific antibodies: rabbit polyclonal anti–Notch-3 (clone M-134; Santa Cruz), mouse mAbs anti-ERK and anti-phosphorylated ERK (Cell Signalling), β-Actin (Sigma-Aldrich), and CA-IX (clone M-75).

**Statistics.** Continuous variables (percentages of dead cells, number of invading cells in Boydren Chamber assays) were analyzed by ANOVA (unequal variance assumed). Post-hoc test (unequal variance assumed) was used to compare more than 2 groups. Non-normally distributed variables (RT-PCR normalized values of mRNA level) were analyzed by 2-sample nonparametric test (Mann-Whitney). Categorical variables (MS and spheroid size distribution) were analyzed by Monte Carlo χ² test. All the tests were implemented in SPSS 10.1 Package (SPSS). A P value less than 0.05 was considered significant.

**Acknowledgments**

This work has been supported by University of Bologna RFO funds-ex 60%, Cornelia Pallotti and Roberto Pallotti Foundation to M. Bonafè, and FIRB project RBNE03K3RZ to P. Chieco. We also thank Fondazione Cassa di Risparmio in Bologna for supporting the Center for Applied Biomedical Research.

Received for publication April 27, 2007, and accepted in revised form December 9, 2007.

Address correspondence to: Massimiliano Bonafè, Department of Experimental Pathology, Via S. Giacomo 12, 40126, Bologna, Italy. Phone: 39-051-636-4009; Fax: 39-051-636-3920; E-mail: massimiliano.bonafe@unibo.it.